GlassScriptPhysician profile
Safa L Ibrahim
NPI 1154778611
$6,518.61
in general payments reported to CMS, 2019-2025
44 companies · $2,474 in 2025
The $2,474 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,039 · 2023: $954 · 2024: $2,053 · 2025: $2,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,421 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,420.67 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,057.62 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $658.71 | 2022-2025 | Evenity, Prolia, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $553.68 | 2022-2025 | |
| Lilly USA, LLC | $399.62 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $367.06 | 2024-2025 | Korlym |
| Abbvie INC. | $330.33 | 2022-2025 | |
| Mannkind Corporation | $289.99 | 2022-2025 | Afrezza |
| Radius Health, INC. | $230.04 | 2023-2025 | Tymlos |
| Insulet Corporation | $181.74 | 2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $163.52 | 2022-2025 | |
| Beta Bionics, INC. | $149.84 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $141.00 | 2024-2025 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $128.84 | 2022-2025 | Isturisa, Signifor Lar |
| Neurocrine Biosciences, INC. | $127.87 | 2025 | |
| Alexion Pharmaceuticals, INC. | $127.63 | 2023-2025 | Strensiq |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $109.20 | 2024-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $108.56 | 2022-2025 | Recorlev, Keveyis |
| Ibsa Pharma INC. | $99.72 | 2022-2024 | Tirosint, Licart, Licart |
| Amryt Pharma Holdings LTD | $88.35 | 2022-2023 | Mycapssa |
| Kyowa Kirin, INC. | $86.48 | 2024-2025 | Crysvita |
| Averitas Pharma INC. | $85.28 | 2024-2025 | Qutenza |
| Ascensia Diabetes Care US INC. | $83.79 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $77.06 | 2023-2025 | Unithroid |
| Azurity Pharmaceuticals, INC. | $74.96 | 2023-2025 | Azmiro, Adthyza |
| Alvogen INC | $68.00 | 2022-2025 | Teriparatide |
| Tandem Diabetes Care, INC. | $63.24 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $61.31 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $59.59 | 2022-2024 | |
| Madrigal Pharmaceuticals | $57.52 | 2025 | Rezdiffra |
| Avvisto Therapeutics, LLC | $52.91 | 2025 | Cycloset |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.80 | 2022-2025 | Jardiance, Synjardy |
| Esperion Therapeutics, INC. | $46.94 | 2025 | Nexletol |
| Sequel Med Tech, LLC | $44.21 | 2025 | Twiist |
| Zealand Pharma US, INC. | $43.74 | 2022 | |
| Currax Pharmaceuticals LLC | $33.88 | 2022-2024 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.92 | 2024 | Cycloset |
| Acella Pharmaceuticals, LLC | $32.26 | 2025 | NP Thyroid 60 |
| Astrazeneca Pharmaceuticals LP | $30.69 | 2022 | |
| Astellas Pharma US INC | $29.04 | 2024-2025 | Veozah |
| Ascendis Pharma Endocrinology INC | $24.80 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $22.30 | 2022 | |
| Medtronic, INC. | $22.10 | 2025 | Minimed 780g |
| Nevro Corp. | $13.20 | 2023 | Senza |
| Theracosbio, LLC | $8.27 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safa Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.